C.R. Bard, Inc. (BCR) Shares Sold by Israel Discount Bank of New York

Israel Discount Bank of New York lowered its position in shares of C.R. Bard, Inc. (NYSE:BCR) by 73.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 605 shares of the medical instruments supplier’s stock after selling 1,715 shares during the quarter. Israel Discount Bank of New York’s holdings in C.R. Bard were worth $192,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of BCR. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its position in C.R. Bard by 70.4% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 460 shares of the medical instruments supplier’s stock valued at $145,000 after acquiring an additional 190 shares during the last quarter. ClariVest Asset Management LLC bought a new stake in C.R. Bard during the first quarter valued at $148,000. SRS Capital Advisors Inc. boosted its position in C.R. Bard by 0.7% during the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock valued at $148,000 after acquiring an additional 4 shares during the last quarter. Parallel Advisors LLC boosted its position in C.R. Bard by 283.8% during the first quarter. Parallel Advisors LLC now owns 499 shares of the medical instruments supplier’s stock valued at $153,000 after acquiring an additional 369 shares during the last quarter. Finally, Bronfman E.L. Rothschild L.P. boosted its position in C.R. Bard by 16.7% during the first quarter. Bronfman E.L. Rothschild L.P. now owns 788 shares of the medical instruments supplier’s stock valued at $196,000 after acquiring an additional 113 shares during the last quarter. 79.34% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts have commented on BCR shares. BidaskClub raised shares of C.R. Bard from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 8th. Zacks Investment Research cut shares of C.R. Bard from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. Finally, BMO Capital Markets reissued a “hold” rating and set a $317.00 price objective on shares of C.R. Bard in a research report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $285.67.

In other news, insider John P. Groetelaars sold 23,687 shares of C.R. Bard stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the sale, the insider now owns 31,445 shares of the company’s stock, valued at approximately $10,022,464.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.80% of the company’s stock.

C.R. Bard, Inc. (NYSE:BCR) traded up 0.62% during trading on Friday, hitting $323.91. 532,025 shares of the stock were exchanged. C.R. Bard, Inc. has a 52 week low of $203.63 and a 52 week high of $324.13. The stock has a market cap of $23.54 billion, a P/E ratio of 42.52 and a beta of 0.60. The stock has a 50 day moving average of $320.21 and a 200-day moving average of $294.66.

C.R. Bard (NYSE:BCR) last announced its earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.08. The firm had revenue of $979.70 million for the quarter, compared to analyst estimates of $976.53 million. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.54 EPS. Equities analysts expect that C.R. Bard, Inc. will post $11.84 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “C.R. Bard, Inc. (BCR) Shares Sold by Israel Discount Bank of New York” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://sportsperspectives.com/2017/09/10/c-r-bard-inc-bcr-shares-sold-by-israel-discount-bank-of-new-york.html.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply